What is the price target for EPIX stock?
7 analysts have analysed EPIX and the average price target is 1.73 USD. This implies a price increase of 761.83% is expected in the next year compared to the current price of 0.2012.
ESSA Pharma Inc (EPIX) Forecast, Price Target & Analyst Ratings
NASDAQ:EPIX • CA29668H7085
Current stock price
0.2012 USD
0 (-1.85%)
At close:
0.1951 USD
-0.01 (-3.03%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ESSA Pharma Inc (EPIX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Dec 15, 2025
- Period
- Q4 / 2025
- EPS Estimate
- -$0.16
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.73
Upside
+ 761.83%
From current price of $0.20 to mean target of $1.73, Based on 7 analyst forecasts
Low
$1.72
Median
$1.73
High
$1.79
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for EPIX. The average price target is 1.73 USD. This implies a price increase of 761.83% is expected in the next year compared to the current price of 0.2012.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.71%
EPIX was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about EPIX.
In the previous month the buy percentage consensus was at a similar level.
EPIX was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-11-04 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2024-11-04 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-11-01 | Jones Trading | Downgrade | Buy -> Hold |
| 2024-05-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-12-13 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-08-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2022-05-12 | Piper Sandler | Maintains | Overweight |
| 2021-08-17 | Oppenheimer | Maintains | Outperform |
| 2021-03-04 | Piper Sandler | Initiate | Overweight |
| 2021-02-25 | HC Wainwright & Co. | Maintains | Buy |
| 2021-02-11 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Dec 15, 2025
- Period
- Q4 / 2025
- EPS Estimate
- -$0.16
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -16.57%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
EPIX is expected to report earnings on 12/15/2025. The consensus EPS estimate for the next earnings is -0.16 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2025 - 2032
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 682.99% | N/A -100.00% | N/A | N/A 30.61% | N/A 15.48% | N/A 9.72% | |||||||||||
| EBITDA YoY % growth | -15.8M | -18.63M -17.91% | -16.01M 14.06% | -11M 31.29% | N/A -19.62% | N/A | N/A | N/A | -32.023M | -34.33M -7.21% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -15.84M | -18.7M -18.06% | -16.06M 14.12% | -11.03M 31.32% | -12.15M -10.15% | -23.93M -96.95% | -37.16M -55.29% | -36.97M 0.51% | -32.141M 13.06% | -34.421M -7.09% | N/A 2.51% | N/A 33.13% | N/A | N/A -3.47% | N/A 1,959.30% | N/A 31.47% | N/A 15.84% | N/A 9.90% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -1.51 43.06% | -1.04 31.13% | -0.97 6.73% | -0.80 17.53% | -0.60 25.00% | -0.64 -6.67% | N/A -13.16% | N/A 74.65% | N/A -172.22% | N/A -1.39% | N/A 1,794.14% | N/A 28.55% | N/A 13.93% | N/A 8.10% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.16 -16.57% | -0.04 78.53% | -0.04 70.86% | -0.04 76.47% | -0.04 75.00% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.14M 7.21% | -2.04M 78.94% | -2.04M 72.36% | -2.04M 58.34% | -2.04M 71.43% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
6.83%
EPS Next 5 Year
72.82%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ESSA Pharma Inc / EPIX Forecast FAQ
What is the next earnings date for EPIX stock?
ESSA Pharma Inc (EPIX) will report earnings on 2025-12-15, after the market close.
What are the consensus estimates for ESSA Pharma Inc (EPIX) next earnings?
The consensus EPS estimate for the next earnings of ESSA Pharma Inc (EPIX) is -0.16 USD and the consensus revenue estimate is 0 USD.
Can you provide the consensus rating for ESSA Pharma Inc stock?
The consensus rating for ESSA Pharma Inc (EPIX) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.